With more COVID-19 vaccines coming to the market, an end to the pandemic is emerging. However, even with efforts to scale up production, the supply of vaccines will limit the speed of immunisation. This will require careful vaccine allocation to maximise social and economic benefits across the US. Several frameworks have been developed to guide vaccine allocation, including one led by the Center for Global Health Innovation (CGHI) Vaccine Economics and Equity Group (VEEG) in partnership with our team at CRA. In European Pharmaceutical Review, we discuss the framework, which provides guidelines for COVID-19 vaccine allocation under conditions of scarcity that consider core public health and ethical principles in the context of optimal benefit for the US economy.
From spreadsheet to strategy: How leading pharma companies transform annual brand planning into competitive advantage
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...